申请人:Celularity, Inc.
公开号:EP3622960A1
公开(公告)日:2020-03-18
Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killers cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g. from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
本文提供了胎盘灌流液、胎盘灌流液细胞、胎盘衍生的中间自然杀伤细胞、来自胎盘和脐带血的联合自然杀伤细胞及其组合。本文还提供了包含上述成分的组合物,以及使用胎盘灌流液、胎盘灌流液细胞、胎盘衍生的中间自然杀伤细胞、组合自然杀伤细胞及其组合物抑制肿瘤细胞、癌细胞等的生长或增殖,以及治疗具有肿瘤细胞的个体的方法。本文还提供了用胎盘灌流液、胎盘灌流液衍生细胞、来自胎盘(如胎盘灌流液)的自然杀伤细胞和/或由来自胎盘(如胎盘灌流液)的自然杀伤细胞和脐带血组成的联合自然杀伤细胞治疗患有肿瘤或移植物抗宿主疾病的个体的方法。